Can a simple nudge make chemo safer? new study explores

NCT ID NCT06559462

Completed Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how to encourage doctors and patients to use DPYD testing before chemotherapy for gastrointestinal cancers. DPYD testing can identify people at higher risk of severe side effects from common chemo drugs. Researchers tested different messages and approaches with 50 participants to see which ones might work best. The goal is to make testing more common and reduce dangerous side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better communicate the importance of DPYD testing, potentially reducing severe side effects from chemotherapy.
What could go wrong: This is a small, completed study focused on message design, not on testing the test itself. It may not lead to widespread changes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DPYD GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm Patient Acceptance of Health Care

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DPYD GENE MUTATION GASTROINTESTINAL CANCER HEALTH CARE SEEKING BEHAVIOR

Contacts and locations

Locations

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.